{"id":"W2749228458","doi":"10.1016/j.conctc.2017.08.007","title":"Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis","year":2017,"lang":"en","type":"article","venue":"Contemporary Clinical Trials Communications","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Eisai; Hokkaido University; Chugai Pharmaceutical; Eisai Canada; AYUMI Pharmaceutical; Daiichi-Sankyo; Daiichi Sankyo Europe; Takeda Pharmaceutical Company","keywords":"Infliximab; Discontinuation; Medicine; Clinical endpoint; Randomized controlled trial; Adverse effect; Internal medicine; Dosing; Clinical trial; Gastroenterology; Surgery; Tumor necrosis factor alpha","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05729071,0.007376812,0.01188758,0.002609481,0.003399125,0.004552735,0.004130271,0.01002371,0.03358318],"category_scores_gemma":[0.04713905,0.003540169,0.006663434,0.003790064,0.004759033,0.002926828,0.002949637,0.01027359,0.01188239],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00427527,"about_ca_system_score_gemma":0.01424025,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001602007,"about_ca_topic_score_gemma":0.003069039,"domain_scores_codex":[0.9426685,0.04278718,0.004426383,0.003713261,0.004200262,0.002204539],"domain_scores_gemma":[0.9830513,0.005169244,0.00322424,0.002001485,0.004061964,0.002491747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8135253,0.01215912,0.002004831,0.05073588,0.005478472,0.0006384485,0.0005939309,0.003016473,0.004957117,0.01348277,0.03685063,0.05655703],"study_design_scores_gemma":[0.8688779,0.02474126,0.003061678,0.01005669,0.002509203,0.0002039577,0.0001346769,0.003576933,0.001053333,0.004214131,0.08135023,0.0002199665],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.001352017,0.001006823,0.002372327,0.0003931199,0.0007547935,0.9918458,0.001165047,0.0001005996,0.001009527],"genre_scores_gemma":[0.001726852,0.0003572861,0.005298499,0.0004211105,0.0001473836,0.9910813,0.000478303,0.00001281314,0.0004764449],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.05729071,"threshold_uncertainty_score":0.3029859,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2497248741944423,"score_gpt":0.5058197798685078,"score_spread":0.2560949056740656,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}